BioXcel Therapeutics (BTAI) announced that the FDA has closed its inspection of a single site in the TRANQUILITY II Phase 3 trial for BXCL501, their treatment for acute agitation in Alzheimer’s dementia patients. The FDA designated the site as ‘Voluntary Action Indicated’ and released the Establishment Inspection Report.
